Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Labcorp Companion Diagnostic for BRAF-Mutated Melanoma Gets FDA Approval

10 August 2026 · By · Wire by Fusion42

Published

10 August 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at precisionmedicineonline.com →

◆ Verified

Fusion42 · 25 August 2026 · Fusion42 review

The US FDA approved Labcorp's PGDx elio tissue complete as a companion diagnostic for detecting BRAF V600E and V600K mutations in melanoma patients.

This Wire brief sits within Fusion42's coverage of Biotech, and 3 sources have reported it.

◆ ◆ The Wire takeaway

You now face a clearer path to US melanoma market access with Labcorp's newly FDA-approved BRAF companion diagnostic. This removes testing uncertainty, letting you align product development or partnerships around a validated diagnostic standard.

◆ Coverage

3 sources · 10 Aug 2026

◆ Related on Wire

◆ Topics

Biotechcompanion-diagnosticfda-approvalbraf-mutationmelanomalabcorp